News

Keros Therapeutics Authorizes Additional $5 Mln Share Repurchase Program

NASDAQ

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Monday announced that its board of directors has approved an additional $5 million share repurchase program.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.